Barclays’s RAPTOR PHARMACEUTICAL CORP COM STK (DE) RPTP Stock Holding History

Barclays’s Portfolio RPTP Stock Details RPTP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-60,000	Closed	-$538K	–	7160
2016 Q3	$538K	Hold	60,000	–	–	﹤0.01%	3160
2016 Q2	$322K	Hold	60,000	–	–	﹤0.01%	3580
2016 Q1	$240K	Sell	60,000 -20,000	-25%	-$80.4K	﹤0.01%	3715
2015 Q4	$400K	Buy	80,000 +8,100	+11%	+$47K	﹤0.01%	3379
2015 Q3	$431K	Buy	+71,900	New	+$881K	﹤0.01%	3489

Barclays's RPTP Position: Q4 2016 in Review

Barclays sold out of RAPTOR PHARMACEUTICAL CORP COM STK (DE) (RPTP) in Q4 2016, closing a stake of 253,084 shares — an estimated $2.27M sold.

Barclays first reported a position in RPTP in Q2 2013 and held it in 13 quarters. The position peaked at $2.27M in Q3 2016. 0 funds tracked by Wall St. Rank hold RPTP as of Q4 2016.

Barclays reported no remaining RAPTOR PHARMACEUTICAL CORP COM STK (DE) position as of Q4 2016 after selling out during the quarter.
Barclays sold 253,084 RAPTOR PHARMACEUTICAL CORP COM STK (DE) shares in Q4 2016, an estimated $2.27M.
Barclays first reported a position in RAPTOR PHARMACEUTICAL CORP COM STK (DE) in Q2 2013 and held it in 13 quarters.
Barclays's RAPTOR PHARMACEUTICAL CORP COM STK (DE) position peaked at $2.27M in Q3 2016.
0 funds tracked by Wall St. Rank held RAPTOR PHARMACEUTICAL CORP COM STK (DE) as of Q4 2016.

Based on Barclays's 13F filing for Q4 2016, filed 14 Feb 2017.